Last reviewed:
Yes. Sharing needles or syringes can introduce blood containing HIV into the bloodstream. The historical average estimate is 63 transmissions per 10,000 needle-sharing exposures to a source with HIV, not a prediction for any used syringe. New sterile equipment, syringe services and appropriate PrEP help prevent infection. After a possible exposure, seek urgent PEP assessment.[1][2][3][5][11]
What the risk actually is
CDC lists 63 transmissions per 10,000 needle-sharing exposures to a source with HIV; the underlying review gives a 95% confidence interval of 41–92. Its comparison figures are 138 for receptive anal sex, 23 for a percutaneous needlestick and 9,250 for transfusion of HIV-contaminated blood. These historical estimates do not incorporate every prevention measure and do not describe the risk from a modern screened blood donation.[1][2]
Repeated exposures can increase cumulative risk. Blood can also contaminate other injection equipment, including cookers, filters and water, so these should not be shared. The 63-per-10,000 estimate specifically concerns needle sharing; it is not a measured risk for every kind of equipment.[1][3]
U=U means that sustained viral suppression prevents sexual transmission. Treatment is expected to reduce transmission through shared injection equipment, but a zero-risk threshold has not been established for this route. Use sterile equipment even when a person has an undetectable viral load.[13][1]
Syringe services programs work — this is settled evidence
Syringe services programs can provide sterile supplies and safe disposal along with testing, vaccinations and connections to medical care and substance use treatment. Their purpose is to make prevention and care accessible to people who inject drugs.[4][3]
CDC’s 2019 infographic summarizes evidence associating syringe services with about a 50% decline in HIV transmission risk. It also reports community benefits from safe disposal and finds that programs do not increase drug use or crime. These are findings across programs, not a guaranteed effect for every individual.[4]
Programs can connect people to treatment. In a Seattle cohort published in 2000, new exchange users were five times as likely to enter drug treatment as never-users. Former exchange users were 3.5 times as likely to stop injecting (adjusted relative risk; 95% confidence limits 2.1–5.9). These observational comparisons concern different participant groups and do not prove that attending a program alone caused the changes.[12][4]
PrEP plus syringe services: use both
For injection-related HIV prevention, CDC recommends daily oral emtricitabine/tenofovir disoproxil fumarate (F/TDF). The estimated reduction of at least 74% comes from oral tenofovir evidence; it should not be applied to every injectable PrEP product. PrEP complements access to new sterile supplies and regular follow-up.[11][1]
After a possible HIV exposure, seek PEP assessment immediately. When indicated, the first dose should begin as soon as possible, ideally within 24 hours and no later than 72 hours, for a 28-day course. Do not wait for symptoms. If more than 72 hours have passed, still seek care for testing and a prevention plan.[5]
The fentanyl and xylazine reality
Xylazine is a non-opioid sedative that may be mixed with fentanyl or other drugs without a person knowing. It can cause dangerous sedation, severe wounds and withdrawal. For a suspected overdose, call 911 and give naloxone when available: naloxone can reverse an opioid component, although it does not reverse xylazine itself.[6]
Seek care early for injection-related wounds, particularly if redness, swelling, drainage or pain is worsening. Wound care helps prevent serious wound complications. Sterile injection equipment, rotating injection sites and allowing damaged skin and veins to heal can reduce injury and infection risks.[6]
Use a new sterile needle and syringe for each injection, and do not share cookers, filters, water or other equipment that may contact blood. Obtain supplies and advice from a syringe services program where available. Carry naloxone and ask about HIV and hepatitis C testing and treatment.[3][4][6]
Florida: the IDEA Act and the IDEA Exchange
Florida’s 2019 IDEA law allows county commissions to authorize syringe exchange programs. This does not mean that a program operates in every county. Florida DOH describes the programs as a way to reduce overdose deaths and prevent HIV and viral hepatitis.[7]
The law's constraints are unusual and worth knowing before you go. Programs cannot use state, county, or municipal funds and must run on grants and private donations; participants' personal identifying information “cannot be collected or used for any purpose”[7]. Each program requires a county ordinance and a letter of agreement with Florida DOH under s. 381.0038 F.S., must partner with the county health department, and must be operated by a licensed hospital, licensed health care clinic, accredited Florida medical school, licensed addiction receiving facility, or a 501(c)(3) HIV/AIDS service organization. IDEA also imposes a strict one-to-one exchange — one new syringe for each one returned — plus education on HIV and viral hepatitis, on-site counseling or referrals for substance use treatment, HIV and viral hepatitis screening or referrals, and naloxone kits or referrals, with annual reports due to county commissioners and DOH by August 1[8].
Miami's IDEA Exchange came first: it “opened its doors on December 1, 2016, on World AIDS Day, as the first pilot Syringe Services Program in Florida” and Florida's first legal program[9]. It does far more than hand out syringes — substance use disorder treatment, HIV prevention, testing and treatment, hepatitis C testing and treatment, wound care, medication management, appointment reminders, and peer navigation for housing and insurance[9].
Florida’s 2023 report counted 174 adult diagnoses attributed to injection drug use alone (about 3.7% of 4,719 diagnoses at age 13 or older), plus 69 in the combined male-to-male sexual contact/injection category. Its care-continuum group of 11,972 people includes those two historical exposure categories, not necessarily people currently injecting: 75% were in care, 69% retained and 62% virally suppressed, compared with 70% suppressed among all people with diagnosed HIV. These descriptive gaps support attention to access without establishing a single cause.[10]
Related questions
What is the actual risk of getting HIV from sharing a needle?
Does sharing cookers, cotton, or water carry HIV risk too?
Yes. Blood can contaminate cookers, filters, water and other injection equipment. Do not share these items. The numerical estimate for needle sharing should not be assigned to every other item.[3]
Does an undetectable viral load prevent HIV transmission through shared needles?
Are syringe exchange programs legal in Florida?
Florida’s IDEA law allows counties to authorize programs, with a county ordinance and Department of Health agreement. It does not guarantee a service in every county. Authorized programs follow requirements including one-for-one exchange and restrictions on public funding and personal identifying information.[7][8]
Related from RiseUpToHIV
References & Sources
- CDC — HIV Risk and Prevention Estimates. Per-act risk table (needle-sharing 63 per 10,000), the note that risks accumulate over time, and PrEP effectiveness of 74–84% among people who inject drugs. ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩
- Patel et al. — Estimating per-act HIV transmission risk: a systematic review. Source of the 63 per 10,000 needle-sharing estimate with its 95% CI of 41–92. ↩ ↩ ↩ ↩
- CDC — How HIV Spreads; needles, syringes and other injection equipment. Source. ↩↩↩↩ ↩ ↩ ↩
- CDC — What are Syringe Services Programs? (2019 infographic); services, HIV prevention association and safe disposal. Source. ↩↩↩↩ ↩ ↩
- CDC — 2025 nonoccupational PEP guidelines; assessment, initiation window and 28-day course. Source. ↩ ↩
- CDC — What You Should Know About Xylazine. Xylazine combined with fentanyl, wound risks, unknowing exposure, and harm-reduction steps including sterile equipment and rotating injection sites. ↩ ↩ ↩
- Florida DOH — Infectious Disease Elimination Act (IDEA). June 27, 2019 signing, DOH's rationale for exchange programs, the ban on public funding, and the prohibition on collecting participants' identifying information. ↩ ↩ ↩ ↩
- Florida DOH — IDEA program requirements and reporting. County ordinance and DOH letter of agreement, eligible operators, the one-to-one exchange rule, required education, counseling, screening, naloxone, and August 1 annual reporting. ↩ ↩
- University of Miami Miller School of Medicine — IDEA Exchange. Opened December 1, 2016 on World AIDS Day as Florida's first legal syringe services program, and its full service list including HCV and HIV care, wound care, and peer navigation. ↩ ↩
- Florida DOH — State of the HIV Epidemic, 2023; adult diagnosis table and care continuum for recorded IDU/MMSC-IDU exposure categories. Source. ↩
- CDC HIV Nexus — Clinical Guidance for PrEP; oral tenofovir evidence for injection exposure. Source. Checked September 21, 2026. ↩ ↩
- Hagan et al. (2000), Reduced injection frequency and increased entry and retention in drug treatment associated with needle-exchange participation in Seattle drug injectors; PMID 11027894. Source. Checked September 21, 2026. ↩
- NIH ARV Guidelines — Treatment as Prevention; sexual transmission evidence and limits for other routes. Source. Checked September 21, 2026. ↩ ↩
Community publications like POZ, Positively Aware, and TheBody inform framing and lived-experience context on RiseUpToHIV. Every clinical, epidemiological, or public-health claim above is anchored to a primary source.